I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Uy Ear reaffirmed a Buy rating on IN8bio (INAB) with a $4.00 price target. Ear, a 4-star analyst in the Healthcare sector, maintains this stance despite IN8bio's broader Strong Buy consensus and $5.00 average price target from TipRanks.
Mizuho Securities analyst Uy Ear maintained a Buy rating on IN8bio yesterday and set a price target of $4.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Ear is a 4-star analyst with an average return of 7.8% and a 44.95% success rate. Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Evolus, and Arcutis Biotherapeutics.
IN8bio has an analyst consensus of Strong Buy, with a price target consensus of $5.00.